RUBICON1,791.00

Rubicon Research Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSHILPAMEDSPARCSTARSUPRIYAPARKHOSPSTHYROCAREMETROPOLISMARKSANSMcap ₹29,568 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations1,754.01,935.8
Other Income7.712.8
Total Income1,761.71,948.6
Expenses
+ Cost of Materials Consumed615.1634.9
+ Purchases of Stock-in-Trade91.3110.0
+ Changes in Inventories-150.4-122.8
+ Employee Benefit Expense256.3283.8
+ Finance Costs42.240.8
+ Depreciation & Amortisation45.350.8
+ Other Expenses541.4579.7
Total Expenses1,441.11,577.2
EBITDA400.2450.2
EBIT355.0399.4
Profit
PBT before Exceptional Items320.5371.4
Pretax Income320.5371.4
+ Current Tax85.3102.9
+ Deferred Tax-11.5-19.7
Tax Expense73.883.1
Net Income246.7288.2
+ Net Income — Continuing Ops246.7288.2
+ Other Comprehensive Income3.0-8.9
Total Comprehensive Income249.7279.3
Net Income to Common246.7288.2
Per Share
Basic EPS15.5217.74
Diluted EPS15.3117.56
Other Comprehensive Income — detail
+ Other Comprehensive Income3.0-8.9
+ Items NOT to be Reclassified to P&L-1.1-0.5
+ Tax on Items NOT to be Reclassified-0.3-0.1
+ Items to be Reclassified to P&L3.8-8.5
Comprehensive Income — Owners of Parent249.7152.7
Comprehensive Income — Non-controlling Interests0.0116.6
Per Share — as-filed variants
Basic EPS — Continuing Operations15.5217.74
Diluted EPS — Continuing Operations15.3117.56
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit1,197.91,313.7
Gross Margin %68.3067.86
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)320.5371.4
Net Income Adj (tax-effected)246.7288.2
EPS Adj15.5217.74
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.00
Paid Up Equity Capital16.516.5
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.